- American City Business Journals•18 hours ago
Shares of Depomed Inc. climbed sharply late Friday as the company beat back an attempt by a trio of generic drug makers to create cheaper forms of the pain drug Nucynta. The ruling in favor of Newark-based Depomed (DEPO) extends the patent life of the drug until December 2025, insuring the company locks up the market and controls the price of Nucynta. The news catapulted Depomed's stock from $24.15 per share to as high as $26.48.
- The Wall Street Journal•23 hours ago
Depomed Inc. said it received a favorable court decision on its patents for its Nucynta painkiller products and expected the ruling would result in market exclusivity through 2025.
- Reuters•23 hours ago
Depomed Inc said a court ruled in favor of the drug maker in a patent litigation over its opioid drug, Nucynta, extending its market exclusivity until 2025. The ruling comes weeks after sources told Reuters that Depomed's talks with potential buyers are expected to start shortly after the court decided on Nucynta, the company's biggest drug. Activist investor Starboard Value LP in April called on Depomed to explore a sale after announcing it had accumulated a stake of close to 10 percent.
Depomed, Inc. (DEPO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||25.60 x 400|
|Ask||25.78 x 300|
|Day's Range||23.54 - 27.02|
|52wk Range||12.25 - 27.02|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-20.53|
|Avg Vol (3m)||1,310,978|
|Dividend & Yield||N/A (N/A)|